These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 16293866

  • 1. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
    Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van Tinteren H, Postmus PE, Golding RP, Biesma B, Schramel FJ, van Zandwijk N, Lammertsma AA, Hoekstra OS.
    J Clin Oncol; 2005 Nov 20; 23(33):8362-70. PubMed ID: 16293866
    [Abstract] [Full Text] [Related]

  • 2. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
    Dooms C, Verbeken E, Stroobants S, Nackaerts K, De Leyn P, Vansteenkiste J.
    J Clin Oncol; 2008 Mar 01; 26(7):1128-34. PubMed ID: 18309948
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J, Khalil AA, Hjorthaug K, Frøkiaer J.
    J Med Imaging Radiat Oncol; 2016 Apr 01; 60(2):231-8. PubMed ID: 26678718
    [Abstract] [Full Text] [Related]

  • 6. Standard uptake value predicts survival in non-small cell lung cancer.
    Okereke IC, Gangadharan SP, Kent MS, Nicotera SP, Shen C, DeCamp MM.
    Ann Thorac Surg; 2009 Sep 01; 88(3):911-5; discussion 915-6. PubMed ID: 19699919
    [Abstract] [Full Text] [Related]

  • 7. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study.
    De Leyn P, Stroobants S, De Wever W, Lerut T, Coosemans W, Decker G, Nafteux P, Van Raemdonck D, Mortelmans L, Nackaerts K, Vansteenkiste J.
    J Clin Oncol; 2006 Jul 20; 24(21):3333-9. PubMed ID: 16849747
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
    Fernandes AT, Mitra N, Xanthopoulos E, Evans T, Stevenson J, Langer C, Kucharczuk JC, Lin L, Rengan R.
    Int J Radiat Oncol Biol Phys; 2012 May 01; 83(1):340-7. PubMed ID: 22104359
    [Abstract] [Full Text] [Related]

  • 10. Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer.
    Collaud S, Lardinois D, Tischler V, Steinert HC, Stahel R, Weder W.
    Eur J Cardiothorac Surg; 2012 Mar 01; 41(3):612-6. PubMed ID: 22219415
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ, Stephans KL, Reddy CA, Djemil T, Srinivas SM, Videtic GM.
    Int J Radiat Oncol Biol Phys; 2010 Nov 15; 78(4):1033-9. PubMed ID: 20472359
    [Abstract] [Full Text] [Related]

  • 13. Are discordant positron emission tomography and pathological assessments of the mediastinum in non-small cell lung cancer significant?
    Tandberg DJ, Gee NG, Chino JP, D'Amico TA, Ready NE, Coleman RE, Kelsey CR.
    J Thorac Cardiovasc Surg; 2013 Oct 15; 146(4):796-801. PubMed ID: 23870158
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of tumor burden measurement using the number of tumors in non-surgical patients with non-small cell lung cancer.
    Zhang H, Wroblewski K, Pu Y.
    Acta Radiol; 2012 Jun 01; 53(5):561-8. PubMed ID: 22661603
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prognostic value of primary tumor FDG uptake for occult mediastinal lymph node involvement in clinically N2/N3 node-negative non-small cell lung cancer.
    Trister AD, Pryma DA, Xanthopoulos E, Kucharczuk J, Sterman D, Rengan R.
    Am J Clin Oncol; 2014 Apr 01; 37(2):135-9. PubMed ID: 23111361
    [Abstract] [Full Text] [Related]

  • 17. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer.
    de Geus-Oei LF, van der Heijden HF, Visser EP, Hermsen R, van Hoorn BA, Timmer-Bonte JN, Willemsen AT, Pruim J, Corstens FH, Krabbe PF, Oyen WJ.
    J Nucl Med; 2007 Oct 01; 48(10):1592-8. PubMed ID: 17873138
    [Abstract] [Full Text] [Related]

  • 18. Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer.
    Banna GL, Anile G, Russo G, Vigneri P, Castaing M, Nicolosi M, Strano S, Gieri S, Spina R, Patanè D, Calcara G, Fraggetta F, Marletta F, Stefano A, Ippolito M.
    Oncology; 2017 Oct 01; 92(1):39-47. PubMed ID: 27832654
    [Abstract] [Full Text] [Related]

  • 19. [Positron emission tomography with 18F-FDG and cancer response to chemotherapy].
    van Ruychevelt V, Garcia C, Meert AP, Berghmans T, Paesmans M, Flamen P, Sculier JP.
    Rev Mal Respir; 2011 May 01; 28(5):618-25. PubMed ID: 21645832
    [Abstract] [Full Text] [Related]

  • 20. Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer.
    Dooms C, van Baardwijk A, Verbeken E, van Suylen RJ, Stroobants S, De Ruysscher D, Vansteenkiste J.
    J Thorac Oncol; 2009 Jul 01; 4(7):822-8. PubMed ID: 19487964
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.